1700015E13Rik Activators
1700015E13Rik activators encompass a range of chemical compounds that stimulate the functional activity of the protein by engaging in various specific signaling pathways within the cellular milieu. Forskolin, known to escalate cAMP levels, thereby activates protein kinase A (PKA), which may phosphorylate proteins and alter their activity, suggesting a potential enhancement of 1700015E13Rik through PKA-mediated phosphorylation events. Similarly, the DNA methylation inhibitor 5-Azacytidine could increase the expression of 1700015E13Rik by reducing the methylation of its promoter, while Trichostatin A, through HDAC inhibition, may facilitate an open chromatin state that enhances gene expression. Ionomycin, by raising intracellular calcium, might activate calcium-dependent kinases that could affect 1700015E13Rik's function if it is calcium-regulated. The activation of protein kinase C (PKC) by PMA could also lead to the phosphorylation of 1700015E13Rik, if it is part of the PKC signaling cascade, while retinoic acid might upregulate 1700015E13Rik through retinoid receptor-mediated gene expression changes.
Moreover, compounds such as Sildenafil citrate and Zaprinast, which inhibit phosphodiesterase type 5, increase cGMP levels that could modulate protein kinase G (PKG) and thereby potentially enhance the activity of 1700015E13Rik if it is part of cGMP-regulated pathways. EGCG, a kinase inhibitor, could lift negative regulation off 1700015E13Rik, indirectly increasing its activity. Inhibition of the PI3K/AKT pathway by LY294002 might relieve suppressive effects on 1700015E13Rik, allowing its function to be amplified. SB431542, by inhibiting the TGF-beta receptor ALK5, could potentiate 1700015E13Rik activity by lessening competing SMAD signaling. Lastly, db-cAMP serves as a synthetic analog that activates PKA, suggesting that it could enhance 1700015E13Rik activity by emulating the action of endogenous cAMP, further solidifying the role of PKA-mediated pathways in the regulation of 1700015E13Rik.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine is a DNA methyltransferase inhibitor, which leads to reduced DNA methylation. Hypomethylation of gene promoters can result in increased gene expression. If the 1700015E13Rik gene promoter is demethylated, its expression and subsequent protein activity might be enhanced. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A inhibits histone deacetylases (HDACs), leading to increased histone acetylation and a more open chromatin state that can promote gene expression. This could indirectly enhance the functional activity of 1700015E13Rik by increasing its expression. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels. Elevated calcium can activate various calcium-dependent kinases and phosphatases, potentially influencing the activity of 1700015E13Rik if its function is calcium-dependent. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which can lead to the phosphorylation and activation of various proteins. If 1700015E13Rik is regulated by PKC or associated signaling pathways, PMA could enhance its activity. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid can influence gene expression through its role as a ligand for retinoic acid receptors. If 1700015E13Rik is responsive to retinoid signaling, its activity could be enhanced by retinoic acid through changes in gene expression. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG has been shown to inhibit certain types of kinases. If 1700015E13Rik is negatively regulated by one of these kinases, EGCG could indirectly enhance its activity by inhibitory modulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can disrupt PI3K/AKT signaling. If 1700015E13Rik's activity is suppressed by PI3K/AKT pathway activity, inhibition by LY294002 could potentially enhance its function. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 is an inhibitor of the TGF-beta type I receptor ALK5, which can modulate SMAD signaling. If 1700015E13Rik is involved in pathways downstream of TGF-beta signaling, inhibition of ALK5 could enhance 1700015E13Rik activity by reducing competitive signaling. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits phosphodiesterases, leading to increased cGMP levels, similar to sildenafil. It could enhance 1700015E13Rik activity if the protein is regulated by pathways involving cGMP. | ||||||
Adenosine 3′,5′-cyclic monophosphate | 60-92-4 | sc-217584 sc-217584A sc-217584B sc-217584C sc-217584D sc-217584E | 100 mg 250 mg 5 g 10 g 25 g 50 g | $116.00 $179.00 $265.00 $369.00 $629.00 $1150.00 | ||
db-cAMP is a cAMP analog that activates PKA. If 1700015E13Rik is regulated by cAMP/PKA signaling, then db-cAMP could enhance its activity by mimicking the effects of endogenous cAMP. | ||||||